Figure 2.

Effect of bicalutamide, enzalutamide and apalutamide in cell viability and proliferation of LNCaP-WT and LNCaP-STEAP1 knockdown cells. Cell viability and proliferation of LNCaP cells following transfection with siRNA for 24 h following treatment with BIC (100 µM), ENZA (10 µM) and APA (10 µM) for 24 h. (A) Percentage of viable cells was determined by the MTT assay. (B) Ki-67 positive cells relative to the total cell number after different conditions were obtained by the immunofluorescence analysis of Ki-67 assay; eight randomly selected fields per microscope cover glass were assessed. (C) Representative fluorescent immunocytochemistry images of Ki-67 labelled cells (red staining) and Hoechst 33342 stained nuclei (blue) were obtained with the AxioImager Z2 fluorescence microscope (magnification, ×400). Results are expressed as percentage of control and fold-variation relative to the LNCaP-WT condition. Error bars indicate mean ± standard error of the mean (n≥2). ***P<0.001 and ****P<0.0001 vs. the LNCaP-WT condition. WT, wild type; STEAP1, six transmembrane epithelial antigen of the prostate 1; siRNA, small interfering RNA; BIC, bicalutamide; ENZA, enzalutamide; APA, apalutamide.